Clinical Trial

Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease Trial

Study acronym: MILED
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated December 24, 2024 (before its estimated June 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a study to determine if early, long-term low dose sirolimus is effective for preventing progression to more advanced stages.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2017-05-10; most recent amendment 2024-12-18.
Status change: Recruiting → Active, Not Recruiting 2024-12-18
Status change: Not Yet Recruiting → Recruiting 2018-04-09
Trial Details
NCT Number NCT03150914
Lead Sponsor University of Cincinnati
Collaborators: National Heart, Lung, and Blood Institute (NHLBI), National Center for Advancing Translational Sciences (NCATS), The LAM Foundation
Conditions LAM, Lymphangioleiomyomatosis
Enrollment 60 participants
Start Date 2018-01-01
Primary Completion 2025-06-30 (estimated)
Study Completion 2025-06-30 (estimated)
Updated on ClinicalTrials.gov 2024-12-24